



1Q 2021 Financial results

1Q 2021

Worldwide sales
\$12.1 billion

GAAP EPS
\$1.25

Non-GAAP EPS
\$1.40

2021 Financial outlook

Continues to expect sales growth of 8% to 12%; full-year 2021 sales estimated to be between \$51.8 billion and \$53.8 billion, including a positive impact from foreign exchange of less than 2%, assuming Organon is part of Merck for the full year

Expects full-year 2021 GAAP EPS to be between \$5.05 and \$5.25; continues to expect Non-GAAP EPS to be between \$6.48 and \$6.68, including a positive impact from foreign exchange of less than 3%, assuming Organon is part of Merck for the full year

Key growth drivers

Oncology

KEYTRUDA[®]
(pembrolizumab) Injection 100 mg

Higher sales and continued uptake



Hospital Acute Care

bridion[®]
(sugammadex) Injection 100 mg/mL*

Higher demand globally

Animal Health



Higher demand in companion animal products and higher sales of companion animal vaccines



Ken Frazier
Chairman & CEO

“While our results this quarter were impacted by the pandemic, the underlying demand for our innovative products remains strong and we remain confident in our future growth prospects.

We are also taking the right steps to evolve Merck’s operating model to continue to create value for patients, shareholders and society.”



Rob Davis
President

“As I transition into the CEO role, one of my immediate priorities is to ensure that our experienced leadership team continues to build on our solid foundation.

Our company is well positioned for strong long-term performance, with scientific innovation remaining the source of our company’s energy and value creation.”

Creating long-term value for patients, employees and shareholders

See investors.merck.com for Merck’s full 1Q earnings release issued April 29, 2021, the associated webcast presentation, forward-looking statement, definitions of non-GAAP measures and reconciliations to the most closely related GAAP measure.